ENDURONYL
LOE ApproachingNDAORALTABLET
Approved
Aug 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 36m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURONYL is an oral tablet approved by Abbott in 1961 under NDA status. The mechanism of action and indications are unknown due to limited data, but the legacy approval date suggests this is an established small-molecule drug with a long commercial history.
LOE Approaching
The product is approaching loss of exclusivity with minimal current linked job openings, suggesting a contracting team focused on legacy management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENDURONYL offers limited career growth opportunities, with zero linked job openings and approaching loss of exclusivity. Career moves to this asset are typically lateral or defensive, focused on protecting installed base and managing profitability in a declining market rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on ENDURONYL at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.